HIGHLIGHTS
- who: Grzegorz Kardas et al. from the ENT, China University of Florence, Italy have published the paper: Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives, in the Journal: (JOURNAL)
- how: A post hoc analysis of the study results found that the 210mg dose reduced exacerbation rates by 64-82% across all four seasons with the greatest reduction in summer and lowest in winter . The drug was tested in one small study in 16 asthmatics with positive results with attenuation of the late asthmatic response after inhalative allergen challenge and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.